HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270007308615v1 47/12/1476    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Parasrampuria, D. A. Articles by Sellers, E. M. Search for Related Content PubMed PubMed Citation Articles by Parasrampuria, D. A. Articles by Sellers, E. M. Social Bookmarking                   What's this?

Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans

From McNeil Pediatrics, Division of McNeil PPC, Fort Washington, Pennsylvania (Dr Parasrampuria, Ms Gu, Dr Ciccone, Dr Silber); DecisionLine Clinical Research Corporation, Toronto, Ontario, Canada (Dr Schoedel, Mr Schuller, Dr Sellers); and Departments of Pharmacology, Medicine, and Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Sellers).

This was a double-blind, placebo-controlled, randomized, 5-period crossover study in 49 healthy subjects with a history of light (occasional) recreational stimulant use, to evaluate the abuse-related subjective effects of oral osmotic-controlled extended-release methylphenidate with comparable doses of immediate-release methylphenidate. Healthy subjects with a history of light recreational stimulant use were enrolled in the study if they demonstrated a positive response to a 20-mg dose of d-amphetamine and a negative placebo response. Enrolled subjects received single doses of placebo, 54 and 108 mg osmotic-controlled extended-release methylphenidate, and 50 and 90 mg immediate-release methylphenidate. For each treatment, pharmacokinetics, pharmacodynamics, and safety were assessed for 24 hours. Subjective data were collected through standard questionnaires and visual analog scales for positive, stimulant, negative, and other effects. Immediate-release and osmotic-controlled extended-release methylphenidate produced expected plasma concentration-time profiles of d-methylphenidate. Both doses of immediate-release methylphenidate (50 and 90 mg) produced statistically significantly higher subjective effects (eg, positive, stimulant) with respect to placebo for all measures. The higher osmotic-controlled extended-release methylphenidate dose of 108 mg also produced statistically significant differences from placebo for most measures. However, the most commonly prescribed therapeutic dose of osmotic-controlled extended-release methylphenidate (54 mg) did not produce significant differences from placebo for most measures. In addition, for comparable dose levels, osmotic-controlled extended-release methylphenidate produced lower positive and stimulant subjective effects than immediate-release methylphenidate, and low-dose immediate-release methylphenidate (50 mg) produced greater subjective effects than high-dose osmotic-controlled extended-release methylphenidate, with many effects demonstrating statistically significant differences. These data support the hypothesis that a formulation can modulate abuse potential by controlling the rate and extent of drug delivery.

Key Words: Methylphenidate • amphetamine • osmotic • extended release • pharmacodynamics • abuse • pharmacokinetics

Address for correspondence: Dolly A. Parasrampuria, PhD, McNeil Pediatrics, Division of McNeil PPC, 420 Delaware Drive, Fort Washington, PA 19034; e-mail: DParasr{at}prdus.jnj.com.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?